(1-mercaptomethyl-3-methylsulfanylpropyl)carbamic acid tert-butyl ester | 135949-99-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代羰基化合物
• 英文名称: (1-mercaptomethyl-3-methylsulfanylpropyl)carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-(4-methylsulfanyl-1-sulfanylbutan-2-yl)carbamate
• CAS: 135949-99-4
• 化学式: C₁₀H₂₁NO₂S₂
• 分子量: 251.414
• InChiKey: CAGCEWKLPDGHAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  64.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1-mercaptomethyl-3-methylsulfanylpropyl)carbamic acid tert-butyl ester 在 methoxycarbonylsulfonic acid chloride 、 三乙胺 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 1.75h， 生成
  参考文献：
  名称：

  MIXED INHIBITORS OF AMINOPEPTIDASE N AND NEPRILYSIN

  摘要：

  披露了氨肽酶N和神经肽酶的混合抑制剂。含有至少其中一种化合物的药物组合物，可单独使用或与吗啡及其衍生物、内源大麻素和内源大麻素代谢抑制剂、GABA衍生物如加巴喷丁或普雷加巴林、度洛西汀或美沙酮结合使用，可用作镇痛剂、抗焦虑剂、抗抑郁剂或抗炎药。

  公开号：

  US20150299116A1

文献信息

• NOVEL AMINO ACID DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC USE THEREOF
  申请人：Fournie-Zaluski Marie-Claude

  公开号：US20110071218A1

  公开（公告）日：2011-03-24

  The disclosure relates to novel compounds of the formula (I) R 1 NH—CH(R 2 )CH 2 —S—S—CH 2 —C(R 3 )(R 4 )—CONH—C(R 5 )(R 6 )—COOR 7 , in which R 1 is a (acyloxy)alkyl carbamate-C(O)—O—C(R 8 )(R 9 )—OC(O)—R 10 group; R 2 is a hydrocarbon chain, a methylene radical substituted by a heterocycle, R 4 is a hydrogen atom and R 3 is a phenyl or benzyl radical, a heteroaryl, a methylene group substituted by a heterocycle or R 3 and R 4 form together a saturated cycle; R 5 and R 6 are hydrogen, a hydrocarbon chain, a phenyl or benzyl radical or R 5 and R 6 form together a saturated cycle; R 7 is hydrogen, a phenyl or benzyl radical, a group of the formula CR 12 (R 13 )C(O)OR 14 or OCR 12 (R 13 )OC(O)R 14 or OCR 12 (R 13 )OC(O)OR 14 . The disclosure also relates to the use of these compounds as a drug, and to a pharmaceutical composition containing said compounds and a pharmaceutically acceptable carrier. The disclosure further relates to the combined use of at least one cannabinoid derivative and/or morphine or one derivative thereof and/or Gaba derivatives for enhancing the analgesic and anti-depressive effect of the compounds of the formula (I).

  该披露涉及到式(I)的新化合物R1NH—CH(R2)CH2—S—S— —C(R3)(R4)—CONH—C(R5)(R6)—COOR7，其中R1是(酰氧基)烷基碳酸酯-C(O)—O—C(R8)(R9)—OC(O)—R10基团；R2是一个碳氢链，一个被杂环取代的亚甲基基团，R4是一个氢原子，R3是一个苯基或苄基基团，一个杂环基团，一个被杂环取代的亚甲基基团或R3和R4一起形成一个饱和环；R5和R6是氢，一个碳氢链，一个苯基或苄基基团，或R5和R6一起形成一个饱和环；R7是氢，一个苯基或苄基基团，一个式CR12(R13)C(O)OR14或OCR12(R13)OC(O)R14或OCR12(R13)OC(O)OR14的基团。该披露还涉及将这些化合物用作药物，以及含有所述化合物和药学上可接受的载体的药物组合物。该披露还涉及至少一种大麻素衍生物和/或吗啡或其衍生物和/或Gaba衍生物的联合使用，以增强式(I)的化合物的镇痛和抗抑郁效果。
• Industrial process for the preparation of (5S, 10S)-10-benzyl-16-methyl-11, 14, 18-trioxo-15, 17, 19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium(E)-3-carboxyacrylate salt
  申请人：PHARMALEADS

  公开号：US10399936B2

  公开（公告）日：2019-09-03

  The present invention relates to an industrial process for the preparation of (5S,10S)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (E)-3-carboxyacrylate salt of following formula (I): wherein X is fumarate. This process comprises the following successive key steps: a kinetic resolution, formation of disulfide compound, peptide coupling, and anion exchange reaction to obtain the desired product of formula (I).

  本发明涉及一种制备下式(I)的(5S,10S)-10-苄基-16-甲基-11,14,18-三氧代-15,17,19-三氧杂-2,7,8-三硫杂-12-氮杂蒽-5-氨基(E)-3-羧基丙烯酸酯盐的工业工艺：其中 X 为富马酸盐。该工艺包括以下连续的关键步骤：动力学解析、二硫化物的形成、肽偶联和阴离子交换反应，以获得所需的式 (I) 产物。
• INDUSTRIAL PROCESS FOR THE PREPARATION OF (5S,10S)-10-BENZYL-16-METHYL-11,14,18-TRIOXO-15,17,19-TRIOXA-2,7,8-TRITHIA-12-AZAHENICOSAN-5-AMINIUM (E)-3-CARBOXYACRYLATE SALT
  申请人：Pharmaleads

  公开号：EP3362433A1

  公开（公告）日：2018-08-22
• INDUSTRIAL PROCESS FOR THE PREPARATION OF (5S, 10S)-10-BENZYL-16-METHYL-11, 14, 18-TRIOXO-15, 17, 19-TRIOXA-2,7,8-TRITHIA-12-AZAHENICOSAN-5-AMINIUM(E)-3-CARBOXYACRYLATE SALT
  申请人：PHARMALEADS

  公开号：US20180305308A1

  公开（公告）日：2018-10-25

  The present invention relates to an industrial process for the preparation of (5S,10S)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (E)-3-carboxyacrylate salt of following formula (I): wherein X is fumarate. This process comprises the following successive key steps: a kinetic resolution, formation of disulfide compound, peptide coupling, and anion exchange reaction to obtain the desired product of formula (I).
• [EN] INDUSTRIAL PROCESS FOR THE PREPARATION OF (5S,10S)-10-BENZYL-16-METHYL-11,14,18-TRIOXO-15,17,19-TRIOXA-2,7,8-TRITHIA-12-AZAHENICOSAN-5-AMINIUM (E)-3-CARBOXYACRYLATE SALT<br/>[FR] PROCÉDÉ INDUSTRIEL POUR LA PRÉPARATION DU SEL (E)-3-CARBOXYACRYLATE DE (5S,10S)-10-BENZYL-16-MÉTHYL-11,14,18-TRIOXO-15,17,19-TRIOXA-2,7,8-TRITHIA-12-AZAHÉNICOSAN-5-AMINIUM
  申请人：PHARMALEADS

  公开号：WO2017064250A1

  公开（公告）日：2017-04-20

  The present invention relates to an industrial process for the preparation of (5S,10S)-10- benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (E)-3-carboxyacrylate salt of following formula (I) : wherein X is fumarate. This process comprises the following successive key steps: a kinetic resolution, formation of disulfide compound, peptide coupling, and anion exchange reaction to obtain the desired product of formula (I).